The FDA has listed a Class II recall, dated 19 August 2026 and ongoing, of compounded semaglutide multi-dose vials made by Apollo Care LLC. The stated reason is the presence of particulate matter, identified as nylon or polyamide and silk or proteinaceous-type material. The listing spans a range of strengths and presentations from the same firm — 0.9 mg/ml and 4.5 mg/ml preparations and several glycine-containing formulations, in vials from 1 ml to 5 ml.
Class II means the FDA judges that use may cause temporary or medically reversible harm, with a remote probability of serious consequences. Particulate matter in an injectable is a sterility and manufacturing-quality failure, not a problem with semaglutide itself, and nothing here reflects on the licensed products.
The reason this matters beyond the United States is the supply route. Compounded semaglutide exists because demand outran the licensed supply, and multi-dose vials with syringes are exactly the presentation that circulates outside regulated channels — including, in India, through weight-loss clinics and online sellers. A patient who arrives with a vial and syringes rather than a branded pen is using a product with no assured provenance and no recall notification reaching them. That is worth asking about directly, because they will not volunteer it, and worth documenting.
- Ask patients on semaglutide what presentation they are using — a vial and syringe is not a licensed pen
- Note that this recall concerns a compounder's product quality, not semaglutide or the licensed products
- Class II means reversible harm is possible; advise patients to stop using an affected vial and seek review
- Inspect any injectable for visible particles before use and discard if present
- This is an FDA action; CDSCO has a separate remit, and Indian patients sourcing compounded product will receive no recall notice at all
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free